Nafamostat

Nafamostat, an anticoagulant, is a synthetic serine protease inhibitor. Nafamostat has anticancer and antivirus effect. Nafamostat induce apoptosis by up-regulating the expression of tumor necrosis factor receptor-1 (TNFR1) . Nafamostat can be used in the development of the pathological thickening of the arterial wall[1][2][3][4].

Product Specifications

CAS Number

81525-10-2

UNSPSC

12352005

Hazard Statement

H302-H315-H319-H335

Target

Apoptosis; Flavivirus; NF-κB; Ser/Thr Protease; TNF Receptor

Type

Reference compound

Related Pathways

Anti-infection; Apoptosis; Metabolic Enzyme/Protease; NF-κB

Applications

Neuroscience-Neurodegeneration

Field of Research

Cancer; Infection

Assay Protocol

https://www.medchemexpress.com/nafamostat.html

Solubility

10 mM in DMSO

Smiles

O=C(OC1=CC=C2C=C(C(N)=N)C=CC2=C1)C3=CC=C(NC(N)=N)C=C3

Molecular Formula

C19H17N5O2

Molecular Weight

347.37

Precautions

P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P330-P362+P364-P403+P233-P405-P501

References & Citations

[1]Uwagawa T, et al. Mechanisms of synthetic serine protease inhibitor (FUT‐175) ‐mediated cell death [J]. Cancer: Interdisciplinary International Journal of the American Cancer Society, 2007, 109 (10) : 2142-2153.|[2]Tajima H, et al. Enhanced invasiveness of pancreatic adenocarcinoma cells stably transfected with cationic trypsinogen cDNA [J]. International journal of cancer, 2001, 94 (5) : 699-704.|[3]Yan Y, et al. Nafamostat mesylate as a broad-spectrum candidate for the treatment of flavivirus infections by targeting envelope proteins [J]. Antiviral research, 2022, 202: 105325.|[4]Sawada M, et al. Prevention of neointimal formation by a serine protease inhibitor, FUT-175, after carotid balloon injury in rats [J]. Stroke, 1999, 30 (3) : 644-650.